Author: Forward Momentum

Artificial Intelligence in Healthcare Symposium

Forward Momentum2022-02-21T16:39:03+00:00

Date: March 4-6, 2022

Venue: Lister Conference Center UofA and Virtual

The Artificial Intelligence in Medicine Student Society (AIMSS) is hosting an in-person/at-home hybrid conference to help inform and educate students on the applications of Artificial Intelligence (AI) and Machine Learning (ML) in the medical field. Dr. Robert Paproski, CTO of Nanostics, will be at the symposium and available to chat about how we use machine learning to diagnose diseases like prostate cancer, bladder cancer, heart disease, and more. Nanostics is proud to be a Silver-level sponsor of this symposium.

Click on the Address Button to learn more and register!

Address

Artificial Intelligence in Healthcare SymposiumForward Momentum2022-02-21T16:39:03+00:00

Nanostics Welcomes New Board Member Mike Schoenberger

Forward Momentum2022-02-05T03:16:10+00:00

Nanostics is EXCITED to announce Mike Schoenberger as its newest Board Member! We also send a huge THANK YOU to outgoing board member Dale Klein for his dedicated service.

Full Article

Nanostics Welcomes New Board Member Mike SchoenbergerForward Momentum2022-02-05T03:16:10+00:00

Antibody titration for flow cytometric analysis of Extracellular Vesicles: Are cell based protocols up to the task?

Forward Momentum2022-02-08T22:58:06+00:00

Date: 06/10/2021

Time: 10:00 am

Venue: Watch on Demand Now by clicking on the Address Button

Desmond Pink, CSO Nanostics

Why is ANTIBODY TITRATION critical to the success of any flow cytometry experiment?

In this webinar, Desmond Pink will investigate and report on antibody titration considerations for EVs, including sample concentration and processing, conjugate decisions, event triggering, platform differences, data processing and analysis, and real-world examples that highlight when antibody titration is necessary.

Abstract

Address

Antibody titration for flow cytometric analysis of Extracellular Vesicles: Are cell based protocols up to the task?Forward Momentum2022-02-08T22:58:06+00:00

BMJ Open Cohort Profile Article: the Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, Canada

Forward Momentum2022-01-04T18:52:15+00:00

The APCaRI Registry and Biorepository, established in 2014, facilitates the collection of clinical and patient-reported data plus biospecimens, to measure prostate cancer outcomes and support the development and clinical translation of innovative technologies. The ultimate goal is to better diagnose and predict outcomes for patients with prostate cancer.

AUTHOR: CATALINA VASQUEZ, MICHAEL KOLINSKY, RUME DJEBAH, MAXWELL UHLICH, BRYAN DONNELLY, ADRIAN S FAIREY, ERIC HYNDMAN, NAWAID USMANI, JACKSON WU, PETER VENNER, DEAN RUETHER, GERALD TODD, MICHAEL CHETNER, R TRAFFORD CRUMP, PERRIN H BEATTY, JOHN D LEWIS

Full Article

BMJ Open Cohort Profile Article: the Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, CanadaForward Momentum2022-01-04T18:52:15+00:00

White Paper: Performance Qualification for MicroFlow Cytometers: Understanding technical limitations to improve your research

Forward Momentum2022-02-05T03:18:15+00:00

As microflow cytometry matures toward clinical applications for extracellular vesicle (EV) analysis, a concerted effort to improve reproducibility has begun. The new MISEV and MISEV MISEV-Flow guidelines are critical to enabling this reproducibility.

AUTHOR: DESMOND PINK, MICHAEL WONG, DIANA PHAM, RENJITH PILLAI, LEANNE STIFANYK, SYLVIA KOCH, REBECCA HIEBERT, OLIVER KENYON, AND JOHN LEWIS

Full Article

White Paper: Performance Qualification for MicroFlow Cytometers: Understanding technical limitations to improve your researchForward Momentum2022-02-05T03:18:15+00:00

Nanostics Re-Opens ClarityDX Prostate Clinical Study with New US Recruitment Site

Forward Momentum2022-01-04T19:06:51+00:00

PR: Nanostics announced the re-opening of their clinical validation study testing ClarityDX Prostate in a real-world setting. The study is also greatly benefiting from further expansion into the US with the addition of a new patient recruitment site at an award-winning United States clinical research institution. ClarityDX Prostate is a novel liquid biopsy test for the early diagnosis of clinically significant prostate cancer. Nanostics is excited to work with this Partner to reach the recruitment numbers and diversity goals of the clinical study.

Full Article

Nanostics Re-Opens ClarityDX Prostate Clinical Study with New US Recruitment SiteForward Momentum2022-01-04T19:06:51+00:00

Nanostics is Developing and Validating a Simple Blood Test to Predict Severity of COVID-19 Disease in SARS-CoV-2 Positive Patients

Forward Momentum2022-01-04T19:08:02+00:00

PR today: Nanostics to use ClarityDX platform to develop & validate a blood test to predict COVID-19 severity in SARS-CoV-2 patients; with Canadian BioSample Repository in Alberta and Century Clinical Research Institute in Florida.

Full Article

Nanostics is Developing and Validating a Simple Blood Test to Predict Severity of COVID-19 Disease in SARS-CoV-2 Positive PatientsForward Momentum2022-01-04T19:08:02+00:00

Alberta Impact with Bryce Lambert, Episode 3, ‘Future of Health’ DynaLIFE Accelerator Lab; benefits of this amazing Medical Lab program

Forward Momentum2022-01-04T19:08:38+00:00

Your technology’s proven in an academic lab⎯now you want it adopted into the healthcare system. The DynaLIFE Accelerator helps startups develop and validate tests in a real-world setting.

Full Article

Alberta Impact with Bryce Lambert, Episode 3, ‘Future of Health’ DynaLIFE Accelerator Lab; benefits of this amazing Medical Lab programForward Momentum2022-01-04T19:08:38+00:00

Validation of ClarityDX Prostate as a Reflex Test to Refine Prediction of Clinically Significant Prostate Cancer: ClinicalTrials.gov ID: NCT03957252

Forward Momentum2022-01-04T19:09:09+00:00

Clinical study to validate ClarityDX Prostate as a reflex test to high PSA levels to refine prediction of clinically significant prostate cancer has begun in a prospective cohort of 2800 men.

Full Article

Validation of ClarityDX Prostate as a Reflex Test to Refine Prediction of Clinically Significant Prostate Cancer: ClinicalTrials.gov ID: NCT03957252Forward Momentum2022-01-04T19:09:09+00:00